http://www.prnewswire.co.uk/cgi/release?id=334028
KOMBOGLYZE™ (saxagliptin and metformin HCl Immediate-Release) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the Marketing Authorisation Application for KOMBOGLYZE™ (saxagliptin and metformin HCl immediate-release fixed dose combination) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as an adjunct to diet and exercise, for the treatment of type 2 diabetes in adults who are not adequately controlled on metformin or those already being treated with the combination of saxagliptin and metformin as separate tablets.
http://en.wikipedia.org/wiki/Saxagliptin
KOMBOGLYZE™ (saxagliptin and metformin HCl Immediate-Release) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the Marketing Authorisation Application for KOMBOGLYZE™ (saxagliptin and metformin HCl immediate-release fixed dose combination) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as an adjunct to diet and exercise, for the treatment of type 2 diabetes in adults who are not adequately controlled on metformin or those already being treated with the combination of saxagliptin and metformin as separate tablets.
http://en.wikipedia.org/wiki/Saxagliptin
